SGLT2 Inhibitors as Add-On Therapy to Metformin for People with Type 2 Diabetes: A Review of Placebo-Controlled Trials in Asian versus Non-Asian Patients
André J Scheen1,2 1Diabetes, Nutrition and Metabolic Disorders, Department of Medicine, CHU Liège, Liège University, Liège, Belgium; 2Clinical Pharmacology Unit, CHU Liège, Center for Interdisciplinary Research on Medicines (CIRM), Liè...
Main Author: | Scheen AJ |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2020-08-01
|
Series: | Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy |
Subjects: | |
Online Access: | https://www.dovepress.com/sglt2-inhibitors-as-add-on-therapy-to-metformin-for-people-with-type-2-peer-reviewed-article-DMSO |
Similar Items
-
Liraglutide and Dulaglutide therapy in addition to SGLT-2 inhibitor and metformin treatment in Indian type 2 diabetics: a real world retrospective observational study
by: S. Ghosal, et al.
Published: (2018-05-01) -
SGLT2 inhibitors: a promising class of antidiabetic agents
by: Camelia DIACONU
Published: (2018-12-01) -
Dysglycaemia in Non-Diabetic Individual from South Asians, Living in UK
by: Aarabi M, et al.
Published: (2005-10-01) -
Dysglycaemia in Non-Diabetic Individual from South Asians, Living in UK
by: Aarabi M, et al.
Published: (2005-03-01) -
Sodium-glucose cotransporter-2 inhibitors in combination with other glucose-lowering agents for the treatment of type 2 diabetes mellitus
by: Sanjay Kalra, et al.
Published: (2018-01-01)